This is of great importance considering the results of a recent study in mice xenografted with human colon cancer cells, suggesting that tumor necrosis factor (TNF) inhibition combined with CTLA-4 and PD-1 immunotherapy may provide a clinically feasible prophylactic strategy regarding some irAEs [35,36]. Here, CTLA4 is linked to colonic neoplasm.